Investor Overview

Latest News Releases

2021 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)

Change
Volume
52 Week High
52 Week Low

03/25/23 12:42 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date	Form	Description	Filing Group	View
02/24/23	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000914475-23-000016.pdf 0000914475-23-000016.rtf 0000914475-23-000016.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
02/24/23	SC 13D/A	An amendment to a SC 13D filing	Other	View HTML 0001193125-23-047416.pdf 0001193125-23-047416.rtf 0001193125-23-047416.xls
02/24/23	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0000899243-23-006093.pdf 0000899243-23-006093.rtf 0000899243-23-006093.xls

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report